In short
Niraparib Tosilate Monohydrate is an innovative drug being studied in several clinical trials for various types of cancer, including ovarian, breast, lung, and endometrial cancers. This article explores the ongoing research into this promising treatment, highlighting its potential benefits and applications across different cancer types and stages. We'll examine how Niraparib is being tested in combination with other therapies and as a maintenance treatment to improve outcomes for cancer patients.
At a glance
- Drug Name
- Niraparib Tosilate Monohydrate
- Drug Class
- PARP (poly ADP-ribose polymerase) inhibitor
- Main Cancer Types Studied
- Ovarian, breast, lung, endometrial, prostate
- Key Trial Phases
- Phase 1b, 2, and 3
- Common Trial Designs
- Randomized, double-blind, placebo-controlled
- Primary Endpoints
- Progression-free survival (PFS), Overall survival (OS)
- Secondary Endpoints
- Objective response rate, Duration of response, Quality of life measures
- Dosage Forms
- Oral capsules or tablets
- Typical Dosing
- 200-300 mg daily, adjusted based on weight and platelet count
- Treatment Duration
- Varies by trial, often until disease progression or unacceptable toxicity
What is Niraparib?
Niraparib tosilate monohydrate, commonly known as niraparib, is a medication used in the treatment of certain types of cancer. It belongs to a class of drugs called PARP inhibitors, which work by interfering with cancer cell growth and survival. Niraparib is marketed under the brand name Zejula and is available as hard capsules or film-coated tablets.
How Niraparib Works
Niraparib is a highly selective poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor. PARP enzymes play a crucial role in repairing damaged DNA in cells. By blocking these enzymes, niraparib makes it harder for cancer cells to repair their DNA, ultimately leading to their death. This mechanism is particularly effective in cancers with defects in DNA repair pathways, such as those with BRCA mutations or homologous recombination deficiency (HRD).
Approved Uses
Niraparib is primarily approved for the treatment of advanced ovarian cancer. Specifically, it is used as a maintenance treatment for patients who have responded to platinum-based chemotherapy in the following situations:
- Advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer
- Recurrent ovarian cancer
- BRCA-mutated ovarian cancer
In some cases, niraparib may also be used to treat certain types of advanced breast cancer with BRCA mutations.
Ongoing Research
Clinical trials are exploring the potential of niraparib in various cancer types and treatment scenarios. Some areas of ongoing research include:
- Use in small cell lung cancer (SCLC) with high SLFN11 expression
- Combination therapy with immunotherapy drugs for ovarian cancer
- Treatment of advanced endometrial cancer
- Maintenance therapy in newly diagnosed advanced ovarian cancer
- Potential use in advanced breast and prostate cancers
How Niraparib is Administered
Niraparib is taken orally, usually once daily. The typical starting dose is 200-300 mg per day, but this may vary based on individual factors such as body weight and platelet count. It's important to take niraparib exactly as prescribed by your healthcare provider.
Potential Side Effects
Like all medications, niraparib can cause side effects. Common side effects may include:
- Fatigue
- Nausea
- Decreased appetite
- Low blood cell counts (anemia, thrombocytopenia, neutropenia)
- Headache
- Insomnia
- Vomiting
- Abdominal pain
More serious side effects, though less common, can include bone marrow problems, high blood pressure, and liver problems. It's crucial to report any side effects to your healthcare provider.
Important Considerations for Patients
If you're considering or currently taking niraparib, keep these points in mind:
- Inform your doctor about all medications, supplements, and herbal products you're taking.
- Regular blood tests will be necessary to monitor your blood cell counts.
- Use effective contraception during treatment and for several months after, as niraparib can harm an unborn baby.
- Do not breastfeed while taking niraparib and for at least 1 month after the last dose.
- Avoid grapefruit and grapefruit juice while taking niraparib, as they may interact with the medication.
Remember, niraparib is a powerful medication that has shown significant benefits for many cancer patients. However, it's essential to work closely with your healthcare team to monitor your progress and manage any side effects that may occur.